RxDoctor Payments Data

William Adams

Dallas, TXNPI 1134153497

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (51.0%), grants and consulting fees — rather than concentrated in one kind of arrangement. Davol Inc. accounts for 67.6% of it on its own, with 18 other manufacturers making up the rest.

$430,983in general payments, 2019–2025

Across 289 payments — averaging $1491.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Davol Inc.$291K
  • AbbVie$95K
  • Mentor Worldwide LLC$38K
  • Sientra, Inc.$2K
  • Motiva USA, LLC$1K
  • TELA Bio, Inc.$846
  • plus $2K from 13 others
$54,905in research payments, 2019–2025

Across 12 payments — averaging $4575.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Davol Inc.$45K
  • Tepha Inc$7K
  • Motiva USA, LLC$3K

What the payments were for

  • Consulting fees$83,88719%
  • Speaking & faculty fees$14,0003%
  • Grants$84,00019%
  • Travel & lodging$2,4181%
  • Food & beverage$18,2074%
  • Gifts$8,4812%
  • Other$219,99151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Penicillin V Potassium11$20

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →